9 Red Days In A Row: BridgeBio Pharma Stock Is Down 8.8%
A nine-day slide in this biotech name puts the focus back on its underlying financial picture.
BridgeBio Pharma (BBIO) stock has fallen 8.8% over nine consecutive trading days. The persistent selling has erased about $1.4 billion from the company’s market value, which now stands at about $15 billion. For anyone holding the stock, this marks a sharp reversal from its performance earlier in the year.
The Streak Next To The S&P 500
Here is how BBIO stock stacks up against the S&P 500 over the streak and the periods around it:
- Karman Stock: 12 Straight Red Days, Down 34%
- How Will Guidewire Software Stock React To Its Upcoming Earnings?
- How Will Samsara Stock React To Its Upcoming Earnings?
- Heico Stock Extends A 7-Day Losing Streak To An 8.4% Loss
- How Will Zscaler Stock React To Its Upcoming Earnings?
- Dycom Industries Stock: 11 Straight Red Days, Down 34%
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | -0.0% | -0.7% |
| 9D (Current Streak) | -8.8% | -1.0% |
| 1M (21D) | -4.2% | 0.4% |
| 3M (63D) | 19.9% | 0.3% |
| YTD 2026 | 0.1% | 11.5% |
| 2025 | 178.8% | 16.4% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
Are the fundamentals justifying this slide?
The recent decline is specific to the company. Over the same 9 trading days, the S&P 500 returned -1.0%. While revenue growth for BridgeBio Pharma is substantial, at 202.4% over the last twelve months versus an S&P 500 median of 8.3%, its profitability metrics show significant strain.
The company’s operating margin over the last twelve months is -67.0%, compared to a median of 18.5% for the index. BridgeBio Pharma also has negative trailing earnings, meaning it does not have a meaningful price-to-earnings multiple.
A streak is information, not an instruction.
A string of losses like this signals that a stock has the market’s attention. The disciplined response is not to react to the momentum itself, but to re-evaluate the business relative to its price. Despite the recent drop, the stock has returned +19.9% over the trailing three months and +47.9% over the trailing twelve months. The current slide provides a moment to weigh the company’s high-growth profile against its lack of profitability.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.